DNLI NASDAQ Week ended 24 Jul 2026

Weekly Investor Report

Denali Therapeutics Inc · Healthcare · Biotechnology

Open interactive chart View report data Download investor PDF
Latest close 23.11 USD
-0.8% latest week
Weekly setup

Mixed setup

The weekly trend is active. Price is 12.2% above the Trend Line and sits at 71.5% of its 52-week range. The latest completed week returned -0.8%, after a -9.6% four-week move. The latest factor snapshot indicates quality is middle-of-the-pack; growth is moderate; valuation is neither clearly cheap nor expensive. Options positioning is volatility with 51/100 conviction, while the latest news-sentiment score is 57/100. Near-term considerations: volume confirmation is below normal; earnings are due in 11d.

Setup score 57 out of 100
Latest Close 23.11 USD 24 Jul 2026
1W Return -0.8% latest completed week
4W Return -9.6% short-term follow-through
12W Return 26.3% quarterly tape
Trend Breadth 80.8% 42 of 52 weeks active
Volume Ratio 0.7x vs 13-week average
What is working
  • The trend backdrop is active with a 9-week active streak.
  • Price is above the Trend Line, keeping the weekly tape constructive.
  • Price is above Fair Value, showing premium demand versus the model.
  • Activity pressure is positive on the latest completed week.
What could go wrong
  • No major top-level risk cluster is currently dominant.
What to watch next
  • Trend Line remains the key weekly regime level.
  • Activity pressure is the gauge to monitor for confirmation or fade.
  • A volume ratio above 1.5x would show stronger participation in the next move.
Price follow-through -0.8% Latest completed week; four-week move -9.6%. Indicator stack 76/71 Trend and activity pressure are weighted against the latest 12-week confirmation window. Trend backdrop Active The trend backdrop defines the current weekly regime. Patient Capital Quiet Activity-pressure buy-signal status for institutional accumulation timing. Options pressure Volatility 51/100 conviction; expected move 14.7%. News sentiment 57/100 62 relevant articles in the latest sentiment read. Event risk 11d Next report is scheduled for 10 Aug 2026; event risk rises as the date approaches.
01 · Price action

Where price is—and whether the trend supports it

The weekly trend is active. Price is 12.2% above the Trend Line and sits at 71.5% of its 52-week range. The latest completed week returned -0.8%, after a -9.6% four-week move.

Study the full chart

52-week price path

Price vs Trend Line and Fair Value
Price Trend Line Fair Value
02 · Volume and demand

Is real participation confirming the move?

Latest weekly volume is 0.7x the 13-week average. Participation is below its recent norm, so price strength is not receiving full volume confirmation.

26-week volume confirmation

Bar height shows volume; colour shows the weekly price direction
30 Jan 6 Feb 13 Feb 20 Feb 27 Feb 6 Mar 13 Mar 20 Mar 27 Mar 3 Apr 10 Apr 17 Apr 24 Apr 1 May 8 May 15 May 22 May 29 May 5 Jun 12 Jun 19 Jun 26 Jun 3 Jul 10 Jul 17 Jul 24 Jul
Up week Down week
Demand beneath price

Activity pressure and institutional-style signals

These indicators assess whether participation is improving beneath the headline price move. They are supporting evidence, not proof of institutional buying.

Activity pressure path

Latest 0.6812-week average 0.50

12-week confirmation

Trend active11/12Active trend-backdrop weeks in the latest 12-week window.
Positive pressure6/12Weeks with constructive activity pressure in the latest 12-week window.
Positive leadership8/12Weeks with positive relative leadership in the latest 12-week window.
Activity pressure0.68Current proprietary activity-pressure read.
Buy signals0Accumulation signal count in the latest 12 weeks.
Reversal markers0No reversal markers

No recent accumulation markers. No reversal markers.

03 · Momentum and leadership

Is performance persistent—and is the stock leading?

Performance is -9.6% over four weeks, 26.3% over 12 weeks, and 69.1% over one year. The current trend has remained active for 9 consecutive weeks.

Performance by holding period

1W-0.8%
4W-9.6%
12W26.3%
26W14.1%
52W69.1%
Active trend streak9 weeks
Active weeks in one year42
Trend breadth80.8%

Activity pressure vs relative leadership

Activity pressureRelative leadership
Pressure0.93Latest activity-pressure read.
Pressure change58.9%Four-week change in activity pressure.
Leadership14.47Latest relative-leadership reading.
RS change-43.6%Four-week change in relative leadership.
04 · Fundamentals and valuation

What investors are paying for—and the quality behind it

The latest factor snapshot indicates quality is middle-of-the-pack; growth is moderate; valuation is neither clearly cheap nor expensive.

Open full factor analysis
Factor week 26 Jul 2026 Financial statements through 31 Dec 2025 Field coverage 67% Model confidence 64%

Relative factor standing

Higher display scores are better. Each score is converted from the underlying universe rank, where rank 1 is best.

Overall factor strength64/100Blend of value, momentum, and quality. Underlying universe rank 37; rank 1 is best.
Value56/100Relative valuation strength. Underlying universe rank 45; rank 1 is best.
Quality55/100Profitability and accounting quality. Underlying universe rank 46; rank 1 is best.
Momentum57/100Medium-term price momentum. Underlying universe rank 44; rank 1 is best.
Growth57/100Revenue and earnings growth. Underlying universe rank 44; rank 1 is best.
How to read this

Quality and valuation are separate questions

A strong company can still carry a demanding valuation. This report shows profitability, growth, balance-sheet strength, and the price paid for those characteristics separately.

Valuation

How much investors are paying for earnings, sales, and cash flow.

P/E
-
Price divided by trailing earnings.
Price / sales
-
Market value relative to trailing revenue.
EV / EBITDA
-
Enterprise value relative to operating cash earnings.
Free-cash-flow yield
-12.1%
Free cash flow as a share of enterprise value.

Business quality

Margins and the return generated on invested capital.

Gross margin
-
Gross profit retained from each unit of revenue.
Operating margin
-
Operating profit retained from revenue.
Free-cash-flow margin
-
Free cash flow generated from revenue.
Return on invested capital
-65.8%
Operating return generated on invested capital.

Growth and financial strength

Recent business growth and accounting strength.

Revenue growth
-
Latest one-year revenue growth.
EPS growth
-
Latest one-year earnings-per-share growth.
Free-cash-flow growth
-
Latest one-year free-cash-flow growth.
Piotroski F-score
3/9
Nine-point accounting-strength checklist.

Shareholder return and balance sheet

Cash returned to owners and financial leverage.

Dividend yield
-
Cash dividends relative to market value.
Buyback yield
-5.2%
Net share repurchases relative to market value.
Shareholder yield
-5.2%
Dividend yield plus net buyback yield.
Net debt / EBITDA
0.7x
Balance-sheet debt relative to operating cash earnings.
05 · Ownership, options, and sentiment

What other market participants are doing

Options, insider transactions, market sentiment, and activity-pressure signals can confirm or challenge the price story. None should be used alone.

Options positioningVolatility

DNLI shows volatility options pressure with a 51/100 conviction score, put-call volume ratio of 0.00, expected move of 14.7%, and Sharemaestro trend signal active.

Conviction51/100
Expected move14.7%
Put/call volume0.00
Pressure90
Speculation11
Volatility84
Trend agreement8
Open options detail
Insider activity17 / 0

17 acquisitions and 0 disposals in the latest 180-day insider tape.

Acquisitions / disposals over the latest 180 days. Insider activity is context, not a stand-alone signal.
News sentiment57/100

Weighted news tone is neutral across 62 relevant articles.

19 positive · 37 neutral · 6 negative
Patient CapitalQuiet

Activity-pressure buy-signal evidence highlights potential institutional accumulation windows.

No recent buy signal
06 · Catalysts and risk

What can move the shares—and how volatile the path has been

Event timing, options-implied movement, drawdown, and weekly return distribution frame the risk around the current setup.

Next earnings11dNext report is scheduled for 10 Aug 2026; event risk rises as the date approaches.
Options expected move14.7%Nearest-chain priced movement where available.
52-week drawdown-15.3%Distance below the 52-week high.
13-week volatility7.3%Standard deviation of weekly returns.

Weekly gains and losses

Latest 26 completed weeks

Each bar is one week. Gains rise above the zero line; losses fall below it. Taller bars mean a larger weekly move.

Weeks higher13 of 2613 weeks finished lower.
Best week+13.7%Week of 3 Apr.
Worst week-11.0%Week of 13 Feb.
Latest week-0.8%Week of 24 Jul.

Shape of recent returns

Strong gains11
Modest gains2
Flat weeks0
Modest losses5
Sharp losses8
Recent vol7.3%13-week weekly-return volatility.
Base vol7.2%52-week weekly-return volatility.
Up/down split29/23Count of positive and negative weeks in the 52-week window.
Average skew6.7% / -5.5%Average positive week versus average negative week.
07 · Sector and peer context

Is this stock leading—or simply moving with its group?

Sector and industry breadth distinguish company-specific strength from a broad group move.

08 · Evidence and weekly data

The underlying research record

Every top-level statement above should be traceable to a stored market, fundamental, event, or positioning observation.

Weekly tape60/100

Trend, activity pressure, participation, and risk combine to a 60/100 tape read.

 Indicator analysis67/100

Latest 12-week confirmation: trend 11/12, activity pressure 6/12, relative leadership 8/12.

Activity pressure 0.68; No reversal markers Factors57/100

O'Shaughnessy factor stack blends value, quality, momentum, and confidence.

Buyback Yield rank 83; Small Cap Core rank 50 Patient CapitalQuiet

Activity-pressure buy-signal evidence highlights potential institutional accumulation windows.

No recent buy signal Options37/100

DNLI shows volatility options pressure with a 51/100 conviction score, put-call volume ratio of 0.00, expected move of 14.7%, and Sharemaestro trend signal active.

Volatility · Volatility expansion watch · Expected move 14.7% Sentiment57/100

Weighted news tone is neutral across 62 relevant articles.

Denali Therapeutics Inc (DNLI) Cash Flow Insiders17 / 0

17 acquisitions and 0 disposals in the latest 180-day insider tape.

 Earnings11d

Next report is scheduled for 10 Aug 2026; event risk rises as the date approaches.
WeekCloseReturnTrend LineFair ValuePressureLeadershipVolumeTrend
24 Jul 202623.11 USD-0.8%20.59 USD19.69 USD0.9314.476.0MOn
17 Jul 202623.29 USD-9.3%20.38 USD19.72 USD1.2814.2313.6MOn
10 Jul 202625.68 USD-0.6%20.17 USD19.76 USD1.1821.397.0MOn
3 Jul 202625.83 USD1.0%19.91 USD19.79 USD1.0625.066.9MOn
26 Jun 202625.57 USD9.7%19.71 USD19.81 USD0.5925.6812.5MOn
19 Jun 202623.31 USD7.6%19.51 USD19.83 USD0.1210.188.0MOn
12 Jun 202621.66 USD11.0%19.33 USD19.87 USD-0.235.4710.4MOn
5 Jun 202619.52 USD-7.2%19.19 USD19.93 USD-0.61-2.608.5MOn
29 May 202621.04 USD12.9%19.04 USD20.00 USD-0.580.247.0MOn
22 May 202618.64 USD0.1%18.88 USD20.07 USD-0.75-8.4410.1MOff
15 May 202618.62 USD-5.1%18.79 USD20.14 USD-0.77-7.468.9MOn
8 May 202619.62 USD7.2%18.73 USD20.22 USD-0.58-2.8210.4MOn
1 May 202618.30 USD-7.9%18.59 USD20.28 USD-0.57-4.509.5MOn
24 Apr 202619.87 USD-3.4%18.49 USD20.33 USD-0.304.835.6MOn
How to use this report

This is a completed-week research summary. It explains the available evidence and its conflicts; it does not predict a guaranteed outcome or replace your own risk assessment. Fundamental figures may refer to an earlier financial reporting period, which is shown above.